GSK PLC Sponsored ADR

GSK Healthcare Drug Manufacturers General

GSK PLC Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $43.1 billion, up 7.44% from fiscal 2024.

Revenue
+3.75%
EPS
−14.7%
Free cash flow
+62.4%
Total debt
+33.2%

Quarter to September 2026, against a year earlier

49.69 0.72 −1.43%
Market cap
$101.0B
P/E
16.7×
Fwd P/E
14.6×
Dividend yield
3.60%
F-score
9/9
Altman Z
2.12
Beneish M
−2.46
Dividend safety
54/100

GSK PLC Sponsored ADR (GSK) Book value per share

Alert me on Book value per share

GSK PLC Sponsored ADR's book value per share at the end of fiscal 2025 was 10.4×, up 26.6% from 8.2× in fiscal 2024. At the end of the quarter to 30 September 2026 it was 12.3×. Over the past ten years it has ranged from 2.3× (fiscal 2017) to 14.7× (fiscal 2021); the current reading is higher than 73% of that period. GSK PLC Sponsored ADR ranks 11th of 21 Drug Manufacturers General companies by book value per share.

Book value per share, annual

Embed this chart

Annual newest first

Period Book value per share Change
FY2025 10.4× 26.63%
FY2024 8.2× 4.43%
FY2023 7.9× 26.63%
FY2022 6.2× (57.70%)
FY2021 14.7× 9.25%
FY2020 13.4× 13.32%
FY2019 11.8× 375.04%
FY2018 2.5× 8.38%
FY2017 2.3× (33.50%)
FY2016 3.5× (50.74%)

Quarterly newest first

Period Book value per share Change
Sep 2026 12.3× 7.26%
Jun 2026 11.5× (1.58%)
Mar 2026 11.7× 12.35%
Dec 2025 10.4× (1.32%)
43 more quarters

Against its own ten years

Low 2.3× High 14.7×
Ten-year median 7.9×
Current reading's percentile 73

Book value per share against peers

What Book value per share is

BV per Share tells an investor how much of a company’s accounting net worth stands behind each share.

(Shareholders Equity (Total) ÷ Shares (Basic, Weighted))

The full definition of Book value per share →

More on GSK